Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk
View/ Open
Author
Lee, Alice W.
Ness, Roberta B.
Roman, Lynda D.
Schildkraut, Joellen M.
Chang-Claude, Jenny
Doherty, Jennifer A.
Menon, Usha
Gayther, Simon A.
Risch, Harvey
Gentry-Maharaj, Aleksandra
Goodman, Marc T.
Modugno, Francesmary
Eilber, Ursula
Moysich, Kirsten B.
Berchuck, Andrew
Rossing, Mary Anne
Jensen, Allan
Wicklund, Kristine G.
Cushing-Haugen, Kara L.
Hogdall, Estrid
Rudolph, Anja
Thompson, Pamela J.
Wilkens, Lynne R.
Kjaer, Susanne K.
Carney, Michael E.
Stram, Daniel O.
Ramus, Susan J.
Wu, Anna H.
Pike, Malcolm C.
Pearce, Celeste Leigh
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1097/AOG.0000000000001387Metadata
Show full item recordCitation
Lee, Alice W., Roberta B. Ness, Lynda D. Roman, Kathryn L. Terry, Joellen M. Schildkraut, Jenny Chang-Claude, Jennifer A. Doherty, et al. 2016. “Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk.” Obstetrics & Gynecology 127 (5) (May): 828–836. doi:10.1097/aog.0000000000001387.Abstract
OBJECTIVE: To describe the association between postmenopausal estrogen-only therapy use and risk of ovarian carcinoma, specifically with regard to disease histotype and duration and timing of use. METHODS: We conducted a pooled analysis of 906 women with ovarian carcinoma and 1,220 women in a control group; all 2,126 women included reported having had a hysterectomy. Ten population-based case-control studies participating in the Ovarian Cancer Association Consortium, an international consortium whose goal is to combine data from many studies with similar methods so reliable assessments of risk factors can be determined, were included. Self-reported questionnaire data from each study were harmonized and conditional logistic regression was used to examine estrogen-only therapy's histotype-specific and duration and recency of use associations. RESULTS: Forty-three and a half percent of the women in the control group reported previous use of estrogen-only therapy. Compared with them, current or recent estrogen-only therapy use was associated with an increased risk for the serous (51.4%, odds ratio [OR] 1.63, 95% confidence interval [CI] 1.27-2.09) and endometrioid (48.6%, OR 2.00, 95% CI 1.17-3.41) histotypes. In addition, statistically significant trends in risk according to duration of use were seen among current or recent postmenopausal estrogen-only therapy users for both ovarian carcinoma histotypes (Ptrend<.001 for serous and endometrioid). Compared with women in the control group, current or recent users for 10 years or more had increased risks of serous ovarian carcinoma (36.8%, OR 1.73, 95% CI 1.26-2.38) and endometrioid ovarian carcinoma (34.9%, OR 4.03, 95% CI 1.91-8.49).CONCLUSION: We found evidence of an increased risk of serous and endometrioid ovarian carcinoma associated with postmenopausal estrogen-only therapy use, particularly of long duration. These findings emphasize that risk may be associated with extended estrogen-only therapy use.
Other Sources
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892111/Terms of Use
This article is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAPCitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:33840774
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)
Comments made during the workflow steps
auth.collection move to HMS